Skip to content Skip to footer
Subscribe Now
Webinar Recap Unveiling Effective Global Market Research Strategies in the Healthcare Industry
EVENTS

Webinar Recap: Unveiling Effective Global Market Research Strategies in the Healthcare Industry

On August 26th 2023, PharmaShots organized a webinar with Octavus Consulting on “Global Market Research Strategies in Healthcare Industry” We were happy to have Utsav Chaurasia, Associate Director, Market Research at Octavus Consulting and Himanshu Sehgal Director, Consulting at Octavus Consulting as our keynote speaker of the webinar. We extend our heartfelt gratitude to everyone who…
August 21, 2023

Read more

VIEWPOINTS_Dr. Beth McQuiston_2023
VIEWPOINTS

Dr. Beth McQuiston Shares her Views on the US FDA Clearance of the First Concussion Blood Test Available for Lab Instruments

Shots: Dr. Beth discussed traumatic brain injuries (TBIs) and the new TBI blood test by Abbott. She told PharmaShots how this blood test measures specific biomarkers, offering objective results within 12 hours, and aiding in evaluating suspected mild TBIs She also talked about how Abbott’s Alinity i lab technology facilitates swift testing, complementing Abbott's i-STAT…
August 21, 2023

Read more

New Drug Designations - July 2023
INSIGHTS+

New Drug Designations – July 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, China, and Korea. This month’s report includes 7 biological drugs, 10 small molecules, 8 cell and gene therapies, 1 radiopharmaceutical, 2 microbiota and 1 diagnostic test  MyoPax’ Satori-01, focused on repairing the Exstrophy-Epispadias Complex sphincter…
August 21, 2023

Read more

VIEWPOINTS

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots: Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…
August 17, 2023

Read more

Medic East Africa and Medlab East Africa 2023
EVENTS

Medic East Africa and Medlab East Africa 2023

East Africa is witnessing an economic and technological boom! Important announcement:In line with providing a better event experience for all attendees, Medic East Africa 2023 has shifted their event 2 days forward.The new dates are 13 - 15 September 2023, at KICC, Nairobi, Kenya.Register now: https://bit.ly/44nKguY#MedicEastAfrica #MedlabEastAfrica Are you ready to explore cutting-edge healthcare and laboratory products?…
August 14, 2023

Read more

VIEWPOINTS_Marija Geertsen1_2023
VIEWPOINTS

Marija Geertsen, Vice President, U.S. Medical Affairs, Lundbeck Shares Insights from 12 Abstracts Presented at AAN 2023

Shots: Marija spoke about the data on Migraine and Brain Health presented at the 75th Annual Meeting of the AAN 2023. The 12 abstracts included the data from post-hoc and real-world analyses of VYEPTI She also talked about a medical symposium sponsored by the company “Migraine: Your Patient, Your Partner. Proactive care for high-frequency, worsening…
August 14, 2023

Read more

VIEWPOINTS_Kathleen Somera-Molina_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New SPINRAZA (nusinersen) Long-Term Data in SMA

Shots: Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years The interview also discusses Biogen’s advances…
August 7, 2023

Read more

Load more